ABSTRACT: Prostate cancer (PC) is the second most common form of cancer in men worldwide. Biomarkers have emerged as essential tools for treatment and assessment since the variability of disease behavior, the cost and diversity of treatments, and the related impairment of quality of life have given rise to a need for a personalized approach. High-throughput technology platforms in proteomics and genomics have accelerated the development of biomarkers. Furthermore, recent successes of several new agents in PC, including immunotherapy, have stimulated the search for predictors of response and resistance and have improved the understanding of the biological mechanisms at work. This review provides an overview of currently established biomarkers in PC, as well as a selection of the most promising biomarkers within these particular fields of development.
Introduction
According to the International Agency for Cancer Research, prostate cancer (PC) is the second most common cancer in men. 1 It is estimated that 1.1 million men worldwide were diagnosed with PC in 2012, accounting for 15% of the cancers diagnosed in men. In North America, PC remains the most common noncutaneous solid tumor. It ranks third in Canada and second in USA as a leading cause of death by cancer in males.
2, 3 Overall, the five-year survival rate is excellent (98.9%) but drops considerably in the metastatic context (28.5%). 4 Fortunately, 80.4% are diagnosed with localized disease. 4 This is due in large part to improvements in screening methods, highlighting the role of biomarkers such as prostate-specific antigen (PSA). A baseline PSA value is a stronger predictive factor of PC than family history or ethnicity. 5 The utility and importance of such biomarkers is underlined by the importance of a personalized approach to PC, given the variability of disease behavior, the diversity of treatments, and the related impairment of quality of life. Aside from their diagnostic and prognostic utilities, biomarkers that are predictive of treatment response are emerging as essential guiding tools, particularly after the expansion of therapeutic options for the castrate-resistant PC (CRPC) population. Furthermore, high-throughput technology platforms in proteomics, genomics, and immunology fields have accelerated the development of biomarkers. This article provides an overview of the currently established biomarkers in PC, as well as a selection of the most promising exploratory biomarkers in development.
Standard Biomarkers for Risk Stratification in PC
Initial patient evaluation and treatment decisions are currently based on a risk stratification scheme that incorporates the three most important prognostic biomarkers at diagnosis: clinical stage, biopsy Gleason grade/score, and serum PSA. Clinical stage is based on the TNM system and is associated with patient survival. 6 The Gleason grade describes the histological features of the cancer cells, from grade 1 (well differentiated) to grade 5 (poorly differentiated), and correlates with clinical behavior also. Since PC is often heterogeneous, a Gleason score (ranging from 2 to 10) is calculated from the sum of the two Gleason grades representing the primary and secondary men with a PSA below 4 ng/mL were at risk for PC, and 15% of these men had high-grade disease. 19 However, when the PSA level was less than 1 ng/mL, the risk of high-grade disease was very low. Moreover, PSA levels above the traditional cutoff of 4 ng/mL reveal the presence of cancer on biopsies in only 25%-30% of patients. 20 Hence, there is no PSA cutoff point with high sensitivity and specificity for PC monitoring in healthy men but rather a continuum of PC risk at all values of PSA.
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PSA derivatives. Refinements to PSA measurements have been proposed, including PSA velocity (rate of change in PSA over time), PSA density (PSA to prostate volume ratio), age-specific PSA levels, and PSA doubling time. [22] [23] [24] [25] However, these have not replaced PSA levels, because they have not been shown to add any incremental value. In the European Randomized Study of Screening for PC (ERSPC), PSA velocity did not independently predict cancer after adjusting for PSA level. 26 Similarly, in the PC Prevention Trial, 27 it was determined that using PSA velocity would increase the number of unnecessary biopsies while missing more high-grade cancers that would be identified just by lowering the PSA cutoff. As for PSA density, measurements are not very convenient because they require transrectal ultrasound or magnetic resonance imaging, and the results are not superior to those obtained with the percentage of free PSA (%fPSA). 28 Moreover, the sensitivity of this test is limited. This was shown by data from a large multicenter screening trial determining that a cutoff of 0.15 ng/mL/cm 3 (a commonly recommended cutoff value) of PSA density would miss nearly 50% of PCs detected in patients with a normal DRE and PSA levels between 4.0 and 10.0 ng/mL. 29 Finally, the clinical utility of age-specific PSA reference ranges remains uncertain. 30 PSA screening controversy. PC screening with PSA levels has been a subject of debate and controversy due to its potential toward overdetection and overtreatment, which can induce patient anxiety. Indeed, the ability of PSA levels to reduce mortality has produced mixed results in recent randomized screening trials. 31, 32 Uncertainty also exists in the practical considerations of testing, such as the age at which to initiate and discontinue the testing, along with its frequency. Various guidelines addressing PC screening have highlighted these issues of uncertainty, prompting the US Preventive Services Task Force to recommend against the use of PSA levels for screening in 2012. 33 Nonetheless, PSA levels still remain the fist-line biomarker option for the detection of PC. As the humoristic title of Vickers and Lilja's 34 article points out: "We need a better marker for PC. How about renaming PSA."
PSA isoforms. In the 1990s, it was discovered that the predominant form of PSA in the serum was in complex with α-1-antichymotrypsin. 35 This facilitated the development of selective immunodetection assays for PSA that was not bound to plasma proteins. 36 Thus, the measurement of fPSA and the calculation of fPSA percentage over total PSA (tPSA = fPSA + PSA bound to α-1-antichymotrypsin) became possible. 37 The %fPSA has been associated with enhanced specificity for early PC detection for men with tPSA between 4 and 10 ng/mL and was initially associated with negative prostate biopsy in several single and multicentric studies. 38 A multicentric trial on the clinical utility of %fPSA reported a sensitivity and specificity of 95% and 20%, respectively, when a single cutoff of 25% was applied for men with tPSA values between 4.0 and 10.0 ng/mL. 39 Consequently, the FDA approved the use of the %fPSA for the early detection of PC in men with PSA levels between 4.0 and 10.0 ng/mL. fPSA itself contains the following three distinct isoforms: (1) proPSA, (2) intact fPSA, and (3) benign PSA. ProPSA and intact fPSA are incompletely processed, single-chain forms that retain some parts of the propeptide sequence. 40 By contrast, benign PSA is a multichain form featuring internal peptide bond cleavages. 41 Most of the current research has focused on proPSA. Initially, most of the studies evaluating the [-5] and [-7] proPSA isoforms discovered that these molecules were no better than fPSA or other PSA-based measurements, in improving PC detection rates, especially in men with a tPSA below 10 ng/mL. 42 However, proPSA interest was rekindled by the identification of [-2]proPSA, a truncated form of proPSA, which has been described as the most prevalent form in tumor extracts and is preferentially expressed in cancerous prostatic epithelium. 43 Multiple studies have suggested a role for this isoform in early detection of PC, as well as for identifying aggressive forms of the disease. 44, 45 Moreover, the velocity of certain isoforms, such as fPSA and proPSA, appears promising in increasing the detection of early PC. 46 Prostate health index. The [-2]proPSA isoform has recently been incorporated in a test known as the prostate health index (PHI), which is developed by Beckman Coulter Inc., in partnership with the NCI's Early Detection Research Network. This test is a mathematical formula of three biomarkers: ([-2]proPSA/fPSA) × PSA 1/2 . The purpose of this test is to distinguish benign and malignant prostatic conditions in patients aged 50 years and older, with a serum PSA between 4 and 10 ng/mL and a normal DRE. Recently, Lazzeri et al 44 have demonstrated that %[-2]proPSA and PHI accurately predict PC in men with a family history of PC and correlate with aggressiveness of the disease. This group also showed that [-2]proPSA, %[-2]proPSA, and PHI values can discriminate PC from chronic histologic prostatic inflammation and benign prostatic hyperplasia, in patients with a PSA between 4 and 10 ng/mL and a normal DRE. 47 Furthermore, meta-analyses published to date demonstrate that the PHI appears to outperform both PSA and %fPSA for the detection of overall and high-grade PC on biopsy. 48, 49 Testing with proPSA and PHI has been approved by the FDA since 2012. PHI, in particular, has been gaining acceptance worldwide, with regulatory approval in more than 50 countries and integration into some PC guidelines. Although PHI is discussed in the 2015 National Comprehensive Cancer Network (NCCN) guidelines for early PC detection, the panel does not recommend its use as firstline screening of all patients because of "limited prospective analyses in US populations." 50 Nonetheless, the panel states that a PHI score of 35 provides an estimate of the probability of PC and is "potentially informative in patients who have never undergone a biopsy or after a negative biopsy." The PHI is also discussed in the Melbourne Consensus Statement 51 and has been added into the smartphone application of the multivariable Rotterdam risk calculator used for clinical decisions.
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4K Score. OPKO Lab Inc. developed the 4K Score, which represents a combination of the following four kallikrein proteins: tPSA, fPSA, intact PSA, and kallikrein-related peptide 2 (hK2), the last of which distinguishes this test from the PHI score. The 4K Score also incorporates clinical information (such as age and history of prior negative biopsy) and provides an estimate of the probability of PC on a given prostatic biopsy. In a retrospective study using the Swedish Cancer Registry, Vickers et al 53 reported that the 4K Score enhanced the predictive accuracy for clinically diagnosed PC when compared to total PSA and age. Another retrospective study conducted on the Rotterdam arm of the European Randomized Study of Screening for PC showed further evidence that the 4K Score provided good accuracy in predicting aggressive disease. 54 A recent meta-analysis from aggregated studies evaluating the four-kallikrein panel showed a statistically significant improvement of 8%-10% in predictive accuracy of PC on biopsy. According to the authors, 48%-56% of biopsies could be avoided using this prediction tool, resulting in substantial financial savings. 55 The 2015 NCCN guidelines 50 do not recommend the 4K Score for first-line screening of all patients, but as stated for the PHI score, the 4K Score is also "potentially informative in patients who have never undergone a biopsy or after a negative biopsy." However, the 4K Score is not yet FDA approved. Prognostic and predictive values of PSA. Despite being criticized as a PC screening biomarker, PSA has many other roles that are broadly accepted. As part of the initial clinical evaluation at diagnosis, PSA is a strong prognostic marker. It is associated with overall survival (OS) alone 56 or as part of nomograms. 57 PSA also reflects the burden of disease in CRPC. 58 Prior to the start of docetaxel chemotherapy in the setting of CRPC, several studies showed that PSA doubling time is prognostic for OS. 59, 60 Associations of PSA with survival in CRPC patients with bone metastases have also been described, and it correlates with bone disease progression and skeletal-related events, regardless of treatment with bone-targeted therapy. 61 Baseline PSA and dynamic PSA changes, such as doubling time and velocity, are associated with PC recurrence and the emergence of metastases. 56, [62] [63] [64] PSA can also improve the correlation of clinical stage and biopsy Gleason sum to the pathological stage at RP. 65 In the IMPACT phase III trial evaluating Sipuleucel-T immunotherapy in CRPC patients, the greatest benefit was observed among patients with better baseline prognostic factors, particularly those with lower baseline PSA values. 66 However, PSA is not a reliable marker of response for this specific immunotherapy. 67 PSA can also be used as a dynamic response biomarker. For instance, PSA is commonly accepted as a response indicator within initial androgen deprivation therapy. 68 In hormone-sensitive patients treated with androgen deprivation or CRPC patients treated with chemotherapy, PSA progression is associated with OS. 69 Similarly, in CRPC treated with abiraterone, PSA kinetics, such as PSA nadir, response rate, time to progression, and doubling time, were highly associated with OS, thus suggesting that PSA might even be used as a surrogate endpoint in this particular population. 70 However, it should be noted that these observations may be treatment specific.
Biomarkers Under Development and Evaluation
Proteomic/genomic biomarkers. In the last decade, proteomic and genomic advancements have accelerated the understanding of PC biology with such technologies as microarray analyses and next-generation genome-wide sequencing. As these platforms have become more available and affordable, an explosion of data has emerged. New approaches now include mostly diagnostic and prognostic panels that integrate somatic mutation signatures. Chosen gene alterations for these panels may be based upon well-known carcinogenic pathways in PC. 71 Others emerge from fishing approaches where unselected genes are filtered to correlate genes and phenotypes. 72 Considerable biostatistic support is required for such strategies to exclude the risk of chance associations. Adherence to standard criteria (such as Reporting of Recommendations for Tumor Marker Prognostic Studies) is also required to reduce potential biases. 73 Other approaches search for key genetic and epigenetic alterations in the peripheral blood, such as circulating tumor cells (CTCs). Most of the proteomic and genomic biomarkers in current development are reported on the NCI's Early Detection Research Network website (http://edrn.nci.nih.gov). The following selection, summarized in Table 1 , represents the most promising tests, some of which are already commercially available. However, comparative studies between these tests do not currently exist.
PC antigen 3 and Progensa. PC antigen 3 (PCA3 or DD3) is a noncoding RNA that is specific to prostate tissue and highly expressed in the presence of malignant disease. PCA3 is of interest because it may be more accurate in outcome prediction than other methods for the early detection of PC at both initial and repeat biopsies. Accordingly, Hologic Inc. has produced the Progensa assay, which has been approved by the FDA since 2012 to help determine whether a repeat biopsy is necessary after a previous negative result. Progensa is a nucleic acid amplification test measuring the concentration of PCA3 and PSA RNA molecules in urine after a DRE. A ratio of PCA3 RNA to PSA RNA is then calculated to provide the PCA3 score. In patients with an initially negative prostate biopsy, a PCA3 score of 25 is associated with a decreased likelihood of true PC. 74 In a meta-analysis of 11 combined clinical studies, of which 7 studies used the Progensa test, the sensitivity ranged from 53% to 69% and the specificity ranged from 71% to 83%. 75 Another recent meta-analysis pooled 11 heterogeneous studies. 76 In the group, including high-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation, the sensitivity and specificity were 72% and 53%, respectively, when using a PCA3 score cutoff of 20. If the cutoff score was increased to 35, the sensitivity and specificity decreased to 49% and 35%, respectively. Recently, Bourdoumis et al 77 conducted a prospective observational study in CRPC patients and demonstrated a strong association between hormonal treatment and the absence of PCA3 expression. The Progensa PCA3 assay has been included in the EAU guidelines for repeat biopsy decision making.
Prostarix Risk Score. Boswick Laboratories offers the Prostarix Risk Score. This test aims to help physicians decide if an initial or repeat biopsy is necessary for patients with a negative DRE and mildly elevated PSA levels. 43 Prostarix measures the concentration of four urinary metabolites, sarcosine, alanine, glycine, and glutamate, which are combined in a logistic regression algorithm. As with the PCA3 assay, the urine is collected after a vigorous DRE. The first studies conducted on such metabolomic profiles have provided evidence that they may serve as promising diagnostic and prognostic tools. [78] [79] [80] [81] TMPRSS2:ERG. Gene rearrangements have been described in many cancers, particularly in hematologic malignancies. The fusion of ERG, a protooncogene of the erythroblast transformation-specific (ETS) family, and transmembrane protease, serine 2 (TMPRSS2) was first reported in 2005 82 and appears to be very specific to PC, with a positive predictive value of 94%. 43 Some studies have suggested a prognostic utility for this fusion gene, but it appears to vary according to specific disease contexts. Boström et al 73 recently reviewed the evidence of its prognostic value in patients following RP and discovered that only 4 out of 10 studies had a significant association with outcome. Furthermore, a recent meta-analysis in this particular population did not show significant association with biochemical relapse or lethal disease. 83 Alternatively, the negative prognostic impact of TMPRSS2:ERG has been reported in watchful waiting cohorts, 84, 85 early-onset disease, 86 and highgrade disease. 87 The TMPRSS2:ERG rearrangement has also been studied as a predictor of response to therapy. Danila et al 88 showed that the rearrangement did not predict the response to abiraterone in CRPC patients, as measured in CTCs. However, the RNA expression of TMPRSS2:ERG in a similar population decreased in 86% of patients undergoing docetaxel chemotherapy. 89 Moreover, ERG expression is also associated with better response to androgen suppression, 90 although some studies have not supported this correlation. 91, 92 In the upcoming PREMIERE-SOGIG phase II trial in metastatic CRPC (mCRPC) patients receiving enzalutamide, the primary objective will be to assess the value of TMPRSS2:ETS in primary tumors and CTCs in predicting PFS. 93 Mi-Prostate Score urine test. Although TMPRSS2:ERG is specific for PC, most tumors have multiple foci and are heterogeneous in TMPRSS2:ERG expression. To overcome this limitation, TMPRSS2:ERG has been combined with other biomarkers. The University of Michigan MLabs has developed the Mi-Prostate Score, a multiplex analysis of urine tests for PCA3, TMPRSS2:ERG, and PSA levels, producing a risk assessment for aggressive disease. In a recent validation study, models applying PCA3 and TMPRSS2:ERG to cohort samples improved the association of PSA with PC and highgrade disease on biopsy. 94 This test is not yet FDA approved. ProMark. Metamark Genetics Inc. has developed the ProMark test which is based on the prostate pathology and comprises an eight-biomarker (CUL2, DERL1, FUS, HSPA9, PDSS2, pS6, SMAD4, and YBX1) proteomic assay for intact tissue biopsies. 95 The test uses a fully automated, quantitative, multiplex immunofluorescence assay. 96 The recent clinical validation study met its two coprimary endpoints, separating favorable from nonfavorable pathology and Gleason score 6 versus non-Gleason score 6 pathology and showing that ProMark provided independent prognostic information relative to current risk stratification systems. 97 ConfirmMDx. MDxHealth offers the ConfirmMDx multiplex DNA methylation assay. This test evaluates epigenetic biomarkers, especially the methylation of glutathione S-transferase pi 1, adenomatous polyposis coli, and Ras association (RalGDS/AF-6). The test aims to predict true negative prostate biopsies from those with possible occult cancer. 43 Two validation studies have been conducted thus far. In the retrospective MATLOC trial, a multivariate model showed that this epigenetic assay was significantly associated with patient outcome with an odds ratio of 3.17 (95% confidence interval 1.81-5.53). 98 In the DOCUMENT study, the assay was independently associated with PC detection in a repeat biopsy collected at an average of 13 months after an initial negative result and demonstrated an 88% negative predictive value. 99 Furthermore, Wojno et al 100 provided evidence for the clinical utility of the test, showing that in 138 patients with a negative initial prostate biopsy and a negative ConfirmMDx test, only 6 patients had repeat biopsies, with no evidence of disease. The current PASCUAL study, which is a controlled prospective study to track the clinical utility of the ConfirmMDx assay in US urologic practices, is expected to be complete in 2017.
Prostate Core Mitomic Test. There is emerging evidence linking mitochondrial function with regulation by oncogenes and tumor suppressors. 101 MDNA Life Sciences Inc. has created the Prostate Core Mitomic Test. The goal of this test is to correctly identify true negative prostate biopsies by utilizing a cancerization field effect to identify the molecular changes in the mitochondrial DNA. 102 In a clinical validation study, this test was associated with a negative predictive value of 91%, a sensitivity of 84%, and a specificity of 54%. 103 This test has not been reviewed by the FDA.
Oncotype DX. Genomic Health Inc. has developed the Oncotype DX PC assay's Genomic Prostate Score (GPS). This tissue-based assay measures the expression of 17 genes related to the following four different molecular pathways: androgen (FAM13C, KLK2, AZGP1, and SRD5A2), stromal response (BGN, COL1A1, and SFRP4), cellular organization (FLNC, GSN, TPM2, and GSTM2), and proliferation (TPX2). Gene expression was quantified by reverse transcription-polymerase chain reaction in the following three studies: a discovery prostatectomy study, a biopsy study, and a prospectively designed, independent clinical validation study testing retrospectively collected needle biopsies from contemporary patients with low to intermediate clinical risk who were candidates for active surveillance. 104 In the validation study, the GPS was associated with high grade and high stage at surgical pathology, as well as high-grade and/or high-stage disease after controlling for established clinical factors. 104 Recently, the GPS correlated with biochemical relapse (after adjusting for NCCN risk group) and time to metastases and was strongly associated with adverse pathology in patients with very low, low, or intermediate risk after RP. 105 The GPS has also shown clinical utility in a study by Dall'Era et al 106 where GPS provided a net increase in recommendations and/or adoption of active surveillance in patients with newly diagnosed PC.
Prolaris score. Myriad Genetics has developed the Prolaris score, which produces a cell cycle progression (CCP) score based on the expression of 46 genes, consisting of 31 cell cycle progression genes and 15 housekeeping genes. The test was first elaborated in 2011 71 and has since been validated in four studies. In the first validation study, the gene panel was associated with PC death in a conservatively managed cohort that had been diagnosed by biopsy and transurethral resection of the prostate. 107 Two other studies reported Prolaris to be an independent prognostic factor for biochemical relapse and metastatic progression after RP. 108, 109 Finally, Freedland et al 110 determined that Prolaris correlated with biochemical relapse and disease-specific survival definitive external beam radiation therapy. When combined with a multivariable score representing postprostratectomy clinical and pathological risk (CAPRA-S score), Prolaris added incremental prognostic information when compared to traditional clinical models. 111 In a recent study, 112 physicians completed surveys regarding treatment recommendations before and after they received and discussed the CCP test results with patients. Overall, 65% of cases showed a change between intended treatment before and after CCP reporting. Recently, the Prolaris panel has also been shown to detect subtle gene expression differences between incidental and clinically detected PCs. 113 However, this expensive test has been criticized for the lack of cost-effectiveness data. 73 According to the 2015 NCCN PC guidelines, 114 the clinical utility of Oncotype DX and Prolaris awaits evaluation by prospective, randomized clinical trials, which remain unlikely to be conducted.
Decipher [115] [116] [117] [118] [119] [120] Clinical utility trials with Decipher were also favorable. In a report by the DECIDE study group, urologists were presented pathology reports and Decipher test results for 24 patients from a previous validation cohort. Following the Decipher genomic classifier results, treatment recommendations changed in 43% of adjuvant and 53% of salvage setting cases. 121 In the PRO-ACT study, 146 PC patients with adverse pathological features following RP were evaluated. 122 After reviewing the genomic classifier test, 60% of high-risk patients were re-classified as low risk. Furthermore, 42.5% of patients who were initially recommended adjuvant therapy were then recommended for observation. In a similar study, Badani et al 123 reported that recommendations for observation after RP increased by 20% for patients who were at low risk for metastasis, whereas recommendations for treatment increased by 16% for patients at high risk for metastasis. Similar to the Prolaris test, the Decipher gene panel's prognostic accuracy was at its highest when combined with clinical models, such as the CAPRA-S score. 115 In other recent studies, Decipher was able to predict the presence of lymph node metastasis in preand post-RP patients 124 as well as metastasis in patients undergoing postoperative, salvage radiation therapy. 117 Decipher can also be recalibrated for time-to-event data. 125 Circulating tumor cells. CTCs have been detected in a majority of epithelial cancers and have emerged as interesting prognostic biomarkers. 126, 127 This subsequently led to the FDA approval of the Veridex Cell Search platform, based on immunomagnetic selection of EPCAM-positive and CD45-negative cells. The number of CTCs has been shown to correlate with OS in PC patients. [128] [129] [130] [131] The IMMC38 study was conducted using the Cell Search platform among CRPC patients receiving chemotherapy and was the first to report the prognostic and predictive role of CTCs. Patients with unfavorable pre-and posttreatment CTC enumeration (5 CTC per 7.5 mL of blood) had shorter OS, and CTC counts had a stronger association with OS than PSA decrement algorithms at all time points. 128 The results of this study also demonstrated the prognostic value of baseline CTC counts as a continuous variable, before and after the initiation of treatment. 131 Subsequently, the prognostic and predictive values of CTCs in the IMMC38 study were prospectively validated in the phase III COU-AA-301 trial, which evaluated abiraterone versus placebo in patients who had received docetaxel. 132 In this study, CTC conversion was associated with an improvement in OS as early as four weeks posttreatment. 133 Further analyses from the same trial revealed that at the individual patient level, a panel containing CTC number and lactate dehydrogenase level served as a surrogate for survival. 134 Additional trials are ongoing to validate these post hoc determined findings. These will require multivariate analyses to determine the value of this biomarker relative to already established, prognostic clinical and laboratory features.
In addition to abiraterone chemotherapy, the prognostic and predictive potential of CTCs appears promising for many new treatments for mCRPC. In patients treated with enzalutamide in the AFFIRM phase III trial, conversion from unfavorable to favorable CTC counts correlated with the OS benefit. 135 Furthermore, CTC counts after treatment with radium 223 may be helpful for monitoring treatment response. 136 The CTCs are particularly interesting since no flare has been described so far, and changes in CTC numbers often occur before increases in PSA levels, highlighting their potential as a promising therapy monitoring marker. 132 One group was even able to sequence the whole genome of CTCs from four patients. 137 However, technical issues remain. First, the Cell Search detection process is dependent on the epithelial phenotype of CTCs, which can miss cells that have a mesenchymal transformation, and the sensitivity of currently available assays is fairly low. 132 Second, the dependency on a human operator for CTC counts may introduce a bias. 138 Finally, the required equipment is costly and not broadly available. 68 Nonetheless, CTC enumeration could be improved with new technologies that are not dependent on EPCAM detection.
Androgen receptor splice variant 7. Perhaps one of the most promising breakthroughs in predictive biomarkers is described in the work of Antonarakis et al. 139 This group examined the clinical relevance of androgen receptor variants from 31 enzalutamide-treated and 31 abiraterone-treated CRPC patients. Specifically, the androgen receptor splice variant 7 (AR-V7) mRNA status was established by reverse transcription-polymerase chain reaction on the CTCs of individual patients. Among the men who received enzalutamide or abiraterone, none of the AR-V7-positive patients had a PSA response. Patients had significantly shorter PSA PFS, clinical or radiographic PFS, and OS. These associations were maintained after adjustment for expression of full-length androgen receptor mRNA. Another study by Steinestel et al 140 also validated the predictive value of AR-V7 and other AR modifications in CTCs. A more recent analysis has shown that AR-V7-positive patients respond to taxane-based chemotherapy in a similar fashion as AR-V7-negative patients. This is one of the first attempts to personalize treatment choice in mCRPC. 141 Large-scale validation of these results are ongoing and will require testing for statistical interaction since clinical endpoints remain the primary objectives of the trial. ARMOR-3-SV phase III trial is the first phase III study to integrate a biomarker in patient selection for specific PC treatment. The study will evaluate the efficacy of galaterone (a new steroidal antiandrogen) in men with mCRPC whose tumors express the AR-V7 splice variant. 142 Bone turnover biomarkers. The prognostic value of bone turnover markers has been evaluated in many studies. Bonespecific alkaline phosphatase and urinary N-telopeptide (Ntx) were associated with skeletal-related events, bone disease progression, and death in patients with solid tumors (including PC) in the placebo arm of two randomized phase III studies. 143 Similar results were reproduced in patients (411 patients with PC) treated with zoledronic acid, and high levels of Ntx were associated to a four-to sixfold increase in the risk of death. 144 Inversely, normalization of the same bone markers within three months of treatment initiation were associated with reduced risks of skeletal complications. 145 Higher levels of bone-specific alkaline phosphatase in serum were also associated with a decrease in OS in men with androgen-independent PC. 146 However, this was not the case for Ntx in that same study. Recent reviews support the utility of bone marker levels to assess disease progression in the metastatic setting and to evaluate bone health during hormonal therapy and response to bisphosphonate therapy. 147, 148 Furthermore, bone turnover markers can potentially guide response to therapy. In a prespecified, exploratory analysis of a multicenter phase III trial, levels of serum type 1 C-telopeptide, tartrate-resistant alkaline phosphatase 5b, and procollagen 1 N-terminal telopeptide decreased significantly in androgen-deprived patients treated with denosumab when compared to placebo.
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Immunologic biomarkers. Initially, PC was not considered as immunogenic in its nature, and first attempts to stimulate an immune response in the prostate were unsuccessful. 150 However, recent evidence demonstrated that PC generates a variety of tumor-associated antigens (TAAs), including PSA, prostatic acid phosphatase, and prostatic-specific membrane antigen, which are capable of producing a clinical response through immunogenicity. 151 Ultimately, this was translated into OS benefits in three phase III clinical trials, including the IMPACT trial, of Sipuleucel-T, an autologous antigenpresenting cell-based vaccine, and led to its approval by the FDA in 2010 and the European Medicine Agency in 2014 for the treatment of asymptomatic or minimally symptomatic mCRPC. [152] [153] [154] Multiple new immunotherapies, including other vaccines and immune checkpoint inhibitors, are currently under investigation, and the demand for predictive and surrogate biomarkers will most certainly increase in the forthcoming years. Such biomarkers could identify responders in the earlier phases of treatments, in which the full effects are often not apparent before weeks to months after initiation. Because OS benefits are generally better demonstrated with immunotherapy than PFS benefits, such biomarkers could also provide surrogate endpoints to trials that would otherwise take years to complete.
Multiple categories of immune biomarkers have already been investigated in PC and include multiple inflammatory biomarkers and mediators, such as cytokines, various cellular and humoral immune responses and signatures, immune checkpoints and regulators, and tumor-infliltrating lymphocytes and other immune cells of the tumor microenvironment. Of note, the study of cellular and humoral immune parameters has produced interesting findings in response to PC itself as well as in the context of different immunotherapies, yielding potential prognostic, predictive, and/or pharmacodynamic biomarkers. New fields are also being developed, such as the genomics of immunological responses. Selected immunological biomarkers are summarized in Table 2 .
Individual cytokines and other inflammatory proteins as biomarkers. Evidence from molecular, experimental, and clinical data suggests that inflammation can contribute or promote prostate carcinogenesis. 155 Concordantly, many biomarkers associated with prostatic inflammation diseases are also present in PC. 156 Among the inflammatory mediators are cytokines, a broad category of small molecules involved in cell signaling, such as chemokines, interferons, interleukins, lymphokines, and tumor necrosis factor. Multiple cytokines have been studied as biomarkers in the context of PC; most of them have generated interest as diagnostic or prognostic tools. Elevated IL-8, TNF-α, and MCP-1 were associated with poorer OS in metastatic PC patients who had started on androgen-deprivation therapy. 157 Further evidence for association between PC progression and two key cytokines, IL-8 and stromal cell-derived factor-1 (CXCL12), has been reviewed. 158 IL-6 can stimulate the growth of androgen-independent cancer cells while suppressing androgen-dependent cells 159 and plays a role in promoting sketetal prostatic tumor growth by interacting with RANKL. 160 IL-6 has also been described in metastatic and CRPC patients, but the association with OS remains uncertain. 161 Transforming growth factor-β1 (TGF-β1) has multiple functions, including cell-mediated immunity. TGF-β1 has been associated with biochemical recurrence post-RP, high Gleason score, and extent of disease. [162] [163] [164] In particular, TGF-β may play a significant role in the progression of PTEN-mutant PC. 165 Moreover, it might have a role as a predictive biomarker for immunotherapy. For instance, TGF-β1 is inversely correlated with in vivo and in vitro immunologic responses to the AE37 peptide vaccination in PC. 166 Similar to recent strategies in the proteomic/genomic field, some cytokines have been combined with other serum biomarkers in a nomogram. In a study by Shariat et al, 167 preoperative plasma levels of TGF-β, IL-6, soluble IL-6 receptor, vascular endothelial growth factor, vascular cell adhesion molecule-1, endoglin, urokinase-type plasminogen activator, and plasminogen activator inhibitor-1 improved the accuracy of standard models associated with biochemical recurrence after RP.
Aside from their prognostic significance, cytokines may also be relevant as predictive biomarkers for chemotherapy. IL-6 and MIC-1 had previously raised interest in the context of docetaxel resistance, and Mahon et al 168 recently reported that in metastatic PC treated with docetaxel, changes in the levels of seven circulating cytokines were associated with progressive disease after completion of one cycle. Moreover, immunological responses in a subset of patients enrolled in the Sipuleucel-T IMPACT phase III trial demonstrated that OS correlated with cytokines and chemokines that were associated with activated antigen-presenting cells activated under secondary to Sipuleucel-T treatment. 169 C-reactive protein (CRP) is an acute-phase protein of the pentraxin family of innate immune regulators involved in inflammation, necrosis, and carcinogenesis. It appears to have prognostic value in different stages of disease. In localized PC patients treated with radiotherapy, elevated CRP was associated with cancer-specific survival, OS, and clinical diseasefree survival. 170 In metastatic patients, high serum CRP level (10 mg/L) was associated with significantly worse OS. 171 In CRPC patients treated with docetaxel and several phase II chemotherapeutic regimens, CRP was independently associated with OS. 172, 173 A recent meta-analysis pooled the results of six studies correlating CRP with OS, in which a statistically significant association was observed between high CRP level and mortality. 174 Based on these analyses, the best estimated CRP cutoff was 12 mg/L.
Toll-like receptors (TLRs) are a family of transmembrane proteins that can recognize highly conserved molecules in invading pathogens. TLR-9 is reportedly increased in poorly differentiated prostate tumors. 175 Reports on the prognostic impact of TLRs in the postdiagnostic setting have been mixed since both upregulation 176 and downregulation 177 have been associated with high PC recurrence. Nonetheless, TLRs now represent a promising therapeutic target. 178 The negative prognostic impact of a high neutrophilto-lymphocyte ratio in pre- 179 and postdocetaxel mCRPC patients 180 has also been documented. High neutrophilto-lymphocyte ratio also holds prognostic and predictive value in mCRPC patients during enzalutamide treatment. 181 Cellular immune responses to PC. Detectable helper T-cell immune correlates of PC were established more than a decade ago when studies, such as McNeel et al, 182 showed that PC patients developed specific responses to PSA and prostatic acid phosphatase of the Th-1 subtype. Remarkably, PSA has also been demonstrated to be immunosuppressive through T-lymphocyte-mediated mechanisms. 183 Other researchers, such as Elkord et al, 184 have shown an impaired PSA-specific, cytotoxic T-cell response in PC patients. However, the prognostic value of PSA-specific, cytotoxic T-cells in peripheral blood outside of therapeutic interventions remains unknown. In one study, it was correlated to circulating prostate-specific, PSA-expressing cells, but not to PSA serum levels. 184 Another study did, however, link a Th-1 profile to a lower risk of PC in a prediagnostic setting. 185 Conversely, a Th-2 profile was observed in post-RP patients who had a worse prognosis. 186 
Cellular immune responses to immunotherapeutic agents.
Most of the cancer vaccine studies to date have used biomarkers based on T-cell responses to TAAs. Early reports, such as Heiser et al, 187 showed that human autologous dendritic cells that were transfected with RNA encoding PSA stimulated prostate-specific cytotoxic T-cells in vitro. Using a PSA-specific DNA vaccine in vivo, cellular immune responses, including a Th-1-skewed response, were reported. 188 In an HLA-A24 + PC patient vaccinated with cytotoxic T-lymphocyte-directed peptides, including PSA, humoral and Th-1 subtype immune responses were elicited. 189 Another group associated superior OS with delayed-type hypersensitivity immune responses in advanced PC patients treated with prostate stem cell antigen and PSA peptide-loaded dendritic cells. 190 In a phase II study of the Onyvax vaccine in mCRPC patients, a Th-1 cytokine release profile was noted in patients responding to restimulation with vaccine lysate. 191 A recent phase II study using the PROSTVAC vaccine showed a trend toward increased OS in patients with a greater than sixfold increase in T-cell response. 192 The immune monitoring within the PROSPECT randomized phase III study with this vaccine may yield further interesting candidates. 193 Recently, cellular responses to ipilimumab, a fully human monoclonal antibody targeting the CTLA-4 checkpoint, were examined in a few studies. In bladder cancer patients treated with anti-CTLA therapy and cystoprostatectomy, there was a higher frequency of CD4 + ICOS(hi) T-cells and higher levels of IFN-γ mRNA, observed in nonmalignant prostate tissue and incidental prostate tumor. 194 In a phase II clinical study of neoadjuvant ipilimumab (NCT01194271), the primary endpoints included the ratio of effector T-cells/Treg-cells, CD4 +
ICOS
+ and CD8 + ICOS + T-cell counts, the presence of NY-ESO-1 antibodies, and total lymphocyte count in peripheral blood, which might emerge as predictive or surrogate biomarkers. Phase III trials of ipilimumab in the CRPC population might yield other potential candidates, although the first reported trial failed to reach its OS primary endpoint. 195 The success of Sipuleucel-T also stimulated the search for meaningful biomarkers. In a phase II clinical trial of preoperative Sipuleucel-T, mCRPC patients receiving treatment had increased T-cell proliferation and IFN-γ in peripheral blood, as well as an increase in infiltrating CD3
+ , CD4 + , FOXP3 -, and CD8
+ T-cells in RP tissues compared to pretreatment biopsies. Interestingly, the magnitude of the circulating immune response did not directly correlate with local tissue response. 196 Unfortunately, the prognostic and predictive impact of these changes remains unknown. Another group has reported on the samples of patients who participated in three randomized clinical trials using Sipuleucel-T. Interestingly, a transient increase in serum eosinophils at week 6 following treatment correlated with an induced immune response, a longer PC-specific survival, and a trend in OS. 197 Thus, transient increases in eosinophil count might hold prognostic and predictive values. Recent analyses from the NeoACT trial report that Sipuleucel-T supports a treatment-induced T-cell migration into the prostate tissue. 198 Other analyses from the STRIDE trial suggest that concurrent or sequential enzalutamide treatment does not impair the Sipuleucel-T immune response. 199 Humoral immune responses to PC. Antibody immunity to PC was demonstrated by McNeel et al, 200 who showed that antibody immunity to PSA and HER-2/neu was significantly higher in PC patients compared to control populations. This response was also increased in patients with androgenindependent disease. Immunoscreening for PC has been successful with multiple TAAs, such as p90 and p62, 201, 202 or antiprostasome antibodies. 203 Prognostic value has also been demonstrated for many antibodies including those against cancer-testis antigen CTSP-1, 204 88 .2% specificity and 81.6% sensitivity in discriminating between the group with PC and the control group, performing better than PSA testing. 207 Similar studies followed, all of which confirmed the potential of different autoantibody panels to discriminate between PC and benign disease. [208] [209] [210] [211] [212] Humoral immune responses to immunotherapeutic agents. Many studies have reported humoral immune responses to new immunotherapeutic agents, although the firm distinction between pharmacodynamic, prognostic, and predictive values of these findings remains to be established. In a phase II randomized clinical trial of combined radiotherapy and a poxvirusbased vaccine encoding PSA, 7 out of 33 patients demonstrated a phenomenon known as antigen spreading, in which a vaccineassociated autoantibody response was induced by four ubiquitously expressed self-antigens, DIRC2, NDUFS1, MRFAP1, and MATN2. 213 The efficacy of vaccine immunotherapies may be enhanced by using predictive, individualized regimens that are tailored by mathematical models encompassing the basic interactions of the vaccine, immune system, and PC cells. 214 Smith et al 215 used a machine-learned Bayesian belief network along with phage immunoblots to identify the patterns of IgG following three months of treatment with different agents. In this report, androgen deprivation showed a different antigen recognition pattern compared to DNA and poxvirus vaccine therapies.
Humoral responses in patients from the IMPACT and ProACT Sipuleucel-T studies were evaluated. After treatment, antigen spreading against multiple secondary antigens occurred in treated patients but not in controls, and the responses to PSA and LGALS3 were associated with an improved OS in the IMPACT trial. 216 Therefore, these responses might hold pharmacodynamic as well as prognostic impacts in this particular population. Antonarakis et al 217 also looked at humoral responses to Sipeuleucel-T in the context of the phase II STAND trial and found that induction of a PA2024 antibody response may correlate with longer time to PSA progression.
Immune checkpoints and regulators. PD-1 and PD-L1. Programmed cell-death receptor 1 (PD-1) is an immunoglobulin superfamily member shown to negatively regulate antigen receptor signaling upon engagement of its ligands (PD-L1 and/or PD-L2). The PD-1-ligand interaction is a major pathway hijacked by tumors to suppress immune control. Immunotherapies targeting this pathway, such as pembrolizumab and nivolumab, have shown promising results in many different tumor types. In the context of CRPC, PD-L1 is emerging as a potential predictive biomarker. In a phase I trial of nivolumab in multiple tumor sites, no objective responses were observed in mCRPC patients (n = 17), but only two of those patients had a biopsy, which were PD-L1 negative. 218 This is not surprising since PC generally shows low levels of PD-L1 expression. 219 However, CD8 + T-lymphocytes infiltrating the prostate have been shown to express PD-1. 220 Interestingly, works by Bishop et al 221 established that resistance to enzalutamide (androgen receptor antagonist) is associated with PD-L1-and PD-L2-positive dendritic cells in both patients and preclinical models and that this resistance mechanism could be overcome by STAT3 inhibition. 222 Further studies are necessary to validate the possible impact of these biomarkers with anti-PD-1/anti-PD-L1 immune checkpoint therapy.
PD-1 has also been reported to be of relevance in the context of other immunotherapeutic agents, such as ipilimumab, the anti-CTLA-4 immune checkpoint inhibitor. In a phase I trial combining ipilimumab and the PROSTVAC vaccine in CRPC patients, lower PD-1 + Tim-3 -CD4 lymphocytes, higher PD-1 -Tim-3 + CD8 lymphocytes, and higher CTLA-Treg lymphocytes were associated with a longer OS. 223 In patients treated with ipilimumab as a single agent, increases in CD4 + effector cells, Tregs, PD-1 + CD4 + effector cells, and PD-1 + CD8 + T-cells were observed but were not associated with OS. However, low pretreatment levels of PD-1 + CD4 + effector cells were related to a longer OS. 224 Moreover, when infiltrating T-cells were analyzed following preoperative Sipuleucel-T, the cells were identified as PD-1 + and Ki-67 + , consistent with activated T-cells. Indeed, high levels of B7-H3 have been associated with tumor progression and poor clinical outcomes. 225, 226 B7-H3 may also have a predictive potential; it has been noted to increase in response to hormone therapy in PC patients after RP.
227
CD73. CD73 is an ectonucleotidase involved in the hydrolysis of extracellular adenosine monophosphate to adenosine, an immunosuppressive molecule. 228 CD73 is expressed in many types of tissues and has been shown to be upregulated in cancer. The CD73-adenosine axis may have adverse prognostic implications in PC patients. 229 Furthermore, the therapeutic potential of CD73 blockade in PC is suggested by preclinical models where anti-CD73 mAb significantly enhanced the activity of both anti-CTLA-4 and anti-PD-1 mAbs against different subcutaneous tumors, including PC. 230 Tumor-infiltrating lymphocytes and the tumor microenvironment. In parallel with other solid tumors, the PC microenvironment has gained increasing attention in the last few years. Early studies already showed immune disturbances where dendritic cells were statistically less in PC compared to normal tissue. 231 In another study, tumor-associated macrophages adjacent to cancer cells were positively associated with Gleason score. 232 Dominance of CD4 + T-cell infiltrates with disturbed effector cell function was also noted by Ebelt et al. 233 Compared to benign nodular prostatic hyperplasia, high-grade prostatic adenocarcinoma had a significantly decreased total immune cell count. 234 The increasing interest in immunosuppressive functions of T-cells further revealed that PC tissue was surrounded by Tregs as well as PD-1 + and PD-L1 + cells. 235 The expression of PD-1 by T-cells may explain why some groups have reported significantly shorter biochemical failure-free survival that is associated with a high density of CD8 + lymphocytes. 229, 236 Other possible mechanisms include CTLA-4 or CD73 expression and IL-35 production. Of note, mast cells have also been studied in the PC tissue, but their clinical significance is still a matter of controversy. 237 Predictive biomarkers in PC tissue are actively investigated in the context of anti-PD-1 immune checkpoint therapy.
Immune biomarkers and genomics. A landmark study by Snyder et al 238 was published in The New England Journal of Medicine in late 2014. This group performed whole exome sequencing on tumors and matched blood samples of 64 melanoma patients treated with the anti-CTLA-4 agents, ipilimumab or tremelimumab. Using genomewide somatic neoepitope analysis and patient-specific HLA typing, candidate tumor neoantigens were identified for each patient, and a neoantigen landscape that was specifically present in tumors with a significant response to treatment was elucidated. Another remarkable study conducted by Rooney et al 239 recently identified 35 recurrently mutated genes showing a positive association with T-cell cytolytic activity, including β-2-microglobulin, HLA-A, -B, and -C, and caspase 8. Genetic amplifications were also associated with high cytolytic activity, including immunosuppressive factors, such as PD-L1/2 and ALOX12B/15B. These genes reveal potential genetic biomarkers for predicting the outcome as well as candidate targets for immunotherapy. Such strategies hold high potential and are beginning to emerge in the specific context of PC. For example, Anastasopoulou et al 240 showed that patients with HLA-A*24 and HLA-DRB*11 alleles had increased immune responses as well as a higher OS after treatment with the AE37 li-key-HER-2/neu polypeptide vaccine, suggesting the potential prognostic and predictive impact of these alleles.
Conclusion and Future Perspectives on PC Biomarkers
Biomarkers in PC is a rapidly expanding field, and recent developments of proteomic/genomic platforms, as well as the rise of immunotherapy (and its mostly unmet need for adequate biomarkers), provide meaningful research opportunities for the upcoming years. Other promising innovations, such as imaging biomarkers, are also being developed. Nonetheless, many challenges still lie ahead. These include the harmonization and validity of assays used in biomarker development, the need for comparative studies for biomarker assays used in similar contexts, the association of correlative immune parameters with clinical endpoints, the development of panels applicable to multiple clinical contexts and therapies, as well as the sample sizes and the cost effectiveness of these tests. Furthermore, selected biomarkers have to provide additional, independent information from already established clinical and pathological variables. Finally, some areas of biomarker research remain largely unexplored and could provide clinically useful information, such as biomarkers predictive of treatment toxicity. Overall, it is rather unlikely that a single biomarker will be able to guide future clinical decisions, and recent trends point to the development of panels combining many different markers, with an underlying statistical complexity that should be designed a priori in clinical trials or meta-analyses. Based on the available body of literature, exciting discoveries in PC biomarker research most certainly lie in the near future.
